Jifang Gong
Peking University
139 Papers
269 Citations
Jifang Gong is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 18, co-authored 82 publications.
Chat about Author
Papers
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
TL;DR: Post-therapy CTC level may help in evaluating therapeutic response in patients with AGC and predicting their prognosis, and changes in CTCs following therapy may be useful in rapidly identifying ineffective treatments and poor prognosis.
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial
Zhihao Lu,Yu Fang,Chang Liu,Xiaotian Zhang,Xiaowei Xin,Yi He,Yanshuo Cao,Xi Jiao,Tianqi Sun,Ying Pang,Yanli Wang,Jun Zhou,Changsong Qi,Jifang Gong,Xicheng Wang,Jian Li,Lili Tang,Lin Shen +17 more
TL;DR: In this paper, the authors assessed the effect of early integration of interdisciplinary supportive interventions to improve prognosis in metastatic esophagogastric cancer (EGC) in the early stages.
94
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.
Ming Lu,Panpan Zhang,Yanqiao Zhang,Zhongwu Li,Jifang Gong,Jie Li,Jian Li,Yan Li,Xiaotian Zhang,Zhihao Lu,Xicheng Wang,Jun Zhou,Zhi Peng,Weifeng Wang,Hui Feng,Hai Wu,Sheng Yao,Lin Shen +17 more
TL;DR: Toripalimab had antitumor activity and safety in treating recurrent or metastatic NENs and patients with positive PD-L1 expression, TMB-H (top 10%), and/or microsatellite instable (MSI-H) might preferentially benefit from the treatment.
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Jifang Gong,Tianshu Liu,Qingxia Fan,Li Bai,Feng Bi,Shukui Qin,Jinwan Wang,Nong Xu,Ying Cheng,Yuxian Bai,Wei Liu,Liwei Wang,Lin Shen +12 more
TL;DR: The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated encouraging efficacy.
Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features
Yakun Wang,Li Sun,Zhongwu Li,Jing Gao,Sai Ge,Cheng Zhang,Jiajia Yuan,Xicheng Wang,Jian Li,Zhihao Lu,Jifang Gong,Ming Lu,Jun Zhou,Zhi Peng,Lin Shen,Xiaotian Zhang +15 more
TL;DR: In this paper, the authors investigated the clinicopathological and molecular characteristics of hepatoid adenocarcinoma of the stomach (HAS) and found that the most frequently mutated gene in both HAS and CGC was TP53, with a mutation rate of 30%.